Organization Announcements

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

 

Paul G. Allen Frontiers Group [to 3 Apr 2021]
https://alleninstitute.org/what-we-do/frontiers-group/news-pr ess/
News
No new digest content identified.

 

BARDA – U.S. Department of HHS [to 3 Apr 2021]
https://www.phe.gov/about/barda/Pages/default.aspx
News
March 31, 2021: HHS launches $500,000 contest for design of new, effective, comfortable masks for general public use
…, the Biomedical Advanced Research and Development Authority (BARDA) is collaborating with the National Institute for Occupational Safety and Health, part of the U.S. Centers for Disease Control and Prevention, on the personal use mask design challenge. NIOSH administers the nation’s respirator approval program.
The first phase of the challenge, which opens today, invites new mask designs that meet specific criteria and asks the submitter to describe how that design idea fits the criteria and solves the hurdles to mask wearing. Up to 10 winning ideas will be selected to split $100,000. Submissions are due by 5 p.m. EDT April 21, 2021…

 

BMGF – Gates Foundation [to 3 Apr 2021]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 3 Apr 2021]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 3 Apr 2021]
https://carb-x.org/
News
03.30.2021  |
CARB-X is funding University of Oxford’s Jenner Institute to develop a new vaccine to prevent gonorrhea
CARB-X is awarding up to US$2 million to the Jenner Institute, part of the University of Oxford, UK, to develop a novel vaccine to prevent gonorrhea, a common sexually-transmitted bacterial infection that has developed resistance to most antibiotics. Under the award, the Institute would be eligible for up to $5.3 million more if the project progresses through certain project milestones, subject to available funding.

 

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 3 Apr 2021]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 3 Apr 2021]
http://cepi.net/
Latest News
CEPI launches funding call to advance development of broadly protective coronavirus vaccines
:: Up to US$200 million in funding to be allocated for development of vaccines that provide broad protection against SARS-CoV-2 and betacoronaviruses.
:: R&D will focus on novel immunogens for use in vaccines that can elicit durable broadly protective immune responses.
:: Funding call forms part of CEPI’s longer term $3.5bn investment strategy, announced earlier in March, 2021, which is being activated now to mitigate the urgent threat posed by COVID-19.
31 Mar 2021

CEPI Board membership updates
30 Mar 2021
CEPI is pleased to announce that Professor Dr Veronika von Messling has been appointed to the Board where she will sit as an Investor representative. Dr von Messling replaces Dr Joachim Klein, who has stood down after 3 years of service.
Alongside her role on the Board, Dr von Messling will also join the Nominations, Compensation, Diversity and Inclusion committee.
Dr von Messling is Director General of the Life Science Division at the German Federal Ministry of Education and Research…

 

DARPA – Defense Advanced Research Projects Agency [to 3 Apr 2021
https://www.darpa.mil/news
News
No new digest content identified.

 

Duke Global Health Innovation Center [to 3 Apr 2021]
https://dukeghic.org/
No new digest content identified.

 

EDCTP [to 3 Apr 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

 

Emory Vaccine Center [to 3 Apr 2021]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

 

European Commission [to 3 Apr 2021]
http://europa.eu/rapid/search-result.htm?query=18&locale=en&page=1
Latest
Statement 31 March 2021
Statement of Commissioner Reynders on the referral of Poland to the European Court of Justice to protect independence of Polish judges and asks for interim measures

Press release 31 March 2021
Rule of Law: European Commission refers Poland to the European Court of Justice to protect independence of Polish judges and asks for interim measures
Today, the European Commission decided to refer Poland to the Court of Justice of the European Union regarding the law on the judiciary of 20 December 2019, which entered into force on 14 February 2020.

Press release 30 March 2021
Syrian crisis: €5.3 billion mobilised by donors for 2021 and beyond at 5th Brussels Conference
At the fifth Brussels Conference on ‘Supporting the future of Syria and the Region’ co-chaired today by the European Union and the United Nations, the international community pledged €5.3 billion for 2021 and beyond for Syria and the neighbouring countries hosting Syrian refugees.

 

European Medicines Agency [to 3 Apr 2021]
http://www.ema.europa.eu/ema/
News & Press Releases
News: AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues (new)
PRAC, Last updated: 31/03/2021

News: EU recommendations for 2021-2022 seasonal flu vaccine composition (new)
Last updated: 30/03/2021

 

European Vaccine Initiative [to 3 Apr 2021]
http://www.euvaccine.eu/
Latest News
No new digest content identified.

 

FDA [to 3 Apr 2021]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements /Selected Details
April 2, 2021 – Coronavirus (COVID-19) Update: April 2, 2021

March 30, 2021 – Coronavirus (COVID-19) Update: March 30, 2021

 

Fondation Merieux [to 3 Apr 2021]
http://www.fondation-merieux.org/
News, Events
Mérieux Foundation co-organized event
Vaccine Acceptance webinars: managing vaccine misinformation in the midst of a pandemic
April 15, 2021 – Virtual Event

 

Gavi [to 3 Apr 2021]
https://www.gavi.org/
News Releases
31 March 2021
Gavi and Save the Children form global partnership to immunise zero-dose and vulnerable children
:: The partnership will focus on reaching children who are currently receiving no routine vaccines and marginalised communities in line with Gavi’s vision to ‘leave no-one behind with immunisation’
:: In addition, the partnership will support equitable access to COVID-19 vaccines by engaging with community champions on joint activities
:: Anuradha Gupta: “A disproportionate number of children who are not receiving vaccines come from hard-to-reach areas including fragile and conflict settings which is why we’re delighted to partner with Save the Children whose worldwide network and deep expertise will enable us to reach them”

29 March 2021
United States to host launch event for Gavi COVAX AMC 2021 investment opportunity
:: The virtual event will bring together world leaders, the private sector, civil society, and key technical partners to galvanize resources and commitment to the Gavi COVAX Advance Market Commitment (AMC)
:: The event, featuring the Secretary of State and the USAID Administrator on behalf of the United States government, and Gavi Board Chair José Manuel Barroso, will take place on April 15
:: The Gavi COVAX AMC is a financing mechanism that supports access to COVID-19 vaccines for 92 lower-income economies

 

GHIT Fund [to 3 Apr 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that
March 31, 2021
GHIT Fund Announces New Investments: A Total of 2.3 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease and Visceral Leishmaniasis, Vaccine for Malaria and Diagnostics for Tuberculosis
… As of March 31, GHIT’s portfolio includes 57 ongoing projects, including 30 in discovery stages, 20 in preclinical and seven in clinical trials (Appendix 3). The total amount of investments since 2013 is 25.1 billion yen (US$236 million).

 

Global Fund [to 3 Apr 2021]
https://www.theglobalfund.org/en/news/
News & Stories
News
The Global Fund’s Sixth Partnership Forums Generate Recommendations for the Next Global Fund Strategy
01 April 2021
The Sixth Partnership Forums ended on 15 March, having convened approximately 350 representatives from across the Global Fund partnership in a series of engaging, inclusive and energetic discussions to contribute to the development of the next Global Fund Strategy…

 

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 3 Apr 2021]
https://www.glopid-r.org/news/
News
No new digest content identified.

 

Hilleman Laboratories [to 3 Apr 2021]
http://www.hillemanlabs.org/
No new digest content identified.

 

Human Vaccines Project [to 3 Apr 2021]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.

 

IAVI [to 3 Apr 2021]
https://www.iavi.org/newsroom
PRESS RELEASES/FEATURES
FEATURES
April 2, 2021
Donor Spotlight: Government of India
IAVI recognizes the Government of India for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and biomedical prevention products for use throughout the world.

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
*News
Press Releases/Announcements
No new digest content identified.

 

 

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

 

IFRC [to 3 Apr 2021]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Global
Statement on International Treaty on Pandemics “We need bold new solutions – both in international and domestic laws – to avoid the same mistakes”
Geneva, 30 March 2021 In response to a common call for an International Treaty on Pandemics by the WHO and world leaders today, Jagan Chapagain, Secretary General of the International Federation of Red Cross Red Crescent Societies, said: We are encouraged by this commitment from the WHO and world leaders today to develop a new treaty on pandemic prevention and response. The COVID-19 response has been hugely impaired by gaps in global cooperation and inequities affecting some of the most vulnerable of our societies. This treaty is an opportunity to address these for the next time.
“We need bold new solutions – both in international and domestic laws – to avoid the same mistakes. These must include a firm commitment to preparedness at all levels of society, including at the community level, and equitable access to testing, vaccines and treatment for all at greatest risk. We must also ensure that health and emergency staff and volunteers are supported to operate safely to provide life-saving aid, and access communities in need. And we must guard against the economic ruin of the poorest and most vulnerable as a result of pandemic responses.
“With our experience in supporting states to develop and implement disaster law and policy around the world, IFRC and its members stand ready to provide their expertise and advice to governments and to support such a treaty to not only be powerful on paper but transformative in reality.”

 

Institut Pasteur [to 3 Apr 2021]
https://www.pasteur.fr/en/press-area
No new digest content identified.

 

IRC International Rescue Committee [to 3 Apr 2021]
http://www.rescue.org/press-release-index
Media highlights [Selected]
Press Release
Statement from the International Rescue Committee on the Generation Equality Forum
April 1, 2021

Statement
Ethiopia: IRC statement on the killing of humanitarian aid workers
April 1, 2021

Press Release
Las continuas caravanas migrantes son síntomas de la emergencia en el norte de Centroamérica, advierte IRC
March 31, 2021

Press Release
Ongoing migrant caravans are symptoms of the emergencies in northern Central America, warns IRC
March 31, 2021

Press Release
México: Postura del IRC sobre la muerte de Victoria Salazar
March 30, 2021

 

IVAC [to 3 Apr 2021]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
Improving the Health of Women and Children in India
March 2021 A Director’s Message
On New Year’s Day in 2021, approximately 68,000 babies were born across India. Their mothers would have traversed the arduous journey of pregnancy to reach the miraculous day of their birth. How many of these babies will be alive and thriving by the end of the year 2021? About five decades ago, […]

 

IVI [to 3 Apr 2021]
http://www.ivi.int/
Selected IVI News, Announcements, Events
International Vaccine Institute and Institut Pasteur Korea Sign MOU for Research and Development of Infectious Disease Therapeutics and Vaccines
April 1, 2021, GYEONGDO-DO and SEOUL, Korea – The International Vaccine Institute (IVI) and the Institut Pasteur Korea (IPK) signed a memorandum of understanding (MOU) for mutual collaboration in the research and development of therapeutics and vaccines for infectious diseases…
Towards the shared goal of improving public health, the IPK and IVI will promote research collaboration and information exchange, holding joint workshops and seminars to connect biomedical scientists and infectious disease experts of the two organizations and their partners worldwide.
In particular, the collaboration combines IPK’s research and technology in infectious disease and IVI’s capabilities and know-how in developing and designing new vaccines and in supporting clinical trials to accelerate new therapeutics and vaccine development. IPK and IVI have common fields of research interest in COVID-19, MERS, Dengue, TB, etc…

 

JEE Alliance [to 3 Apr 2021]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

Johns Hopkins Center for Health Security [to 3 Apr 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 3 Apr 2021]
http://www.msf.org/
Latest [Selected Announcements
Democratic Republic of Congo
In DRC, measles is spreading and killing again in what seems to be a never-ending fight
Project Update 31 Mar 2021

Coronavirus COVID-19 pandemic
“Only vaccination will end the ferocious spread of COVID-19 in Iraq”
Op-Ed 31 Mar 2021

Tuberculosis
Sustainable solutions for children and adolescents at risk of drug-resistant tuberculosis
Project Update 30 Mar 2021

 

National Academy of Medicine – USA [to 3 Apr 2021]
https://nam.edu/programs/
Accessed 3 April 2021
Programs
Advancing Pandemic and Seasonal Influenza Vaccine Preparedness and Response
An International Committee will inform and facilitate efforts to advance global influenza pandemic preparedness. This International Committee will provide an iterative, interactive, multi-disciplinary, expert-informed process for assessing the global impact that capabilities, technologies, processes, and policies developed for COVID-19 could have on pandemic and seasonal influenza global preparedness and response, especially regarding vaccine development.
Upcoming Events:
:: Overview of Vaccine Science: Establishing Priorities to Improve Influenza Vaccines (April 15)
:: Major Barriers to Effective Global Coordination and Financing for Influenza Vaccination- Day 1 (April 9)
:: Major Barriers to Effective Global Coordination and Financing for Influenza Vaccination- Day 2 (April 16)
Past Events:
Overview of Vaccine Science: Existing Evidence and Lessons from COVID-19 (March 30)

 

National Vaccine Program Office – U.S. HHS [to 3 Apr 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

 

NIH [to 3 Apr 2021]
http://www.nih.gov/news-events/news-releases
News Releases
NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins
March 31, 2021 — Early-stage trial to evaluate safety and immunogenicity.

CDC and NIH bring COVID-19 self-testing to residents in two locales
March 31, 2021 — Participating households will receive free month-long supply of rapid tests aimed at reducing community transmission.

T cells recognize recent SARS-CoV-2 variants
March 30, 2021 — NIH research suggests protective effects of vaccination remain intact.

 

UN OCHA Office for the Coordination of Humanitarian Affairs [to 3 Apr 2021]
https://www.unocha.org/
Press Releases
No new digest content identified.

 

PATH [to 3 Apr 2021]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

 

Sabin Vaccine Institute [to 3 Apr 2021]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 3 Apr 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
1 April 2021
President of Afghanistan declares ‘unwavering support’ for a People’s Vaccine for COVID-19

1 April 2021
New study recommends strategies to serve the under-protected Caribbean transgender community

31 March 2021
UNAIDS joins human rights community in mourning Christof Heyns, legal academic and expert

31 March 2021
(Wo)man in the Mirror: seeing your true self

30 March 2021
Solidarity fund helping transgender people during the COVID-19 pandemic

30 March 2021
Fighting transphobia and violence one social media post at a time

30 March 2021
Transgender communities in Asia and the Pacific respond to COVID-19 through activism

 

UNDP United Nations Development Programme [to 3 Apr 2021]
http://www.undp.org/content/undp/en/home/presscenter.html
Latest from News Centre
UNDP releases SDG Impact Standards for Bond Issuers
SDG Impact Standards are already being piloted in the market with New Development Bank’s (NDB) SDG bond issuance in China Interbank Bond Market earlier this month.
Posted on April 1, 2021

New UNDP study reveals the magnitude of limited debt relief eligibility for developing economies
Two-thirds of external ‘debt service at risk’ is not covered by current relief initiatives, putting at risk years of progress on poverty and the future resources needed to deal with climate change
Posted on April 1, 2021

 

UNESCO [to 3 Apr 2021]
http://en.unesco.org/news
Selected Latest News
No new digest content identified.

 

UNHCR Office of the United Nations High Commissioner for Refugees [to 3 Apr 2021]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected Announcements
News Comment: Six refugees among 137 killed in Niger’s recent attack
This news comment is attributable to Gillian Triggs, UNHCR’s Assistant High Commissioner for Protection
1 Apr 2021

 

 

News comment: UNHCR calls on Myanmar’s neighbours to protect people fleeing violence
This news comment is attributable to Gillian Triggs, UNHCR’s Assistant High Commissioner for Protection
31 Mar 2021

 

 

UNHCR alarmed at brutal attacks by insurgent armed group in Mozambique
30 Mar 2021

 

 

UNHCR rushing support and aid to Rohingya refugees affected by last week’s massive fire
30 Mar 2021

 

 

United Nations Chiefs urge donors to support record appeals for Syrians and the region
Joint OCHA/UNHCR/UNDP Press Release
29 Mar 2021

 

UNICEF [to 3 Apr 2021]
https://www.unicef.org/media/press-releases
Selected press releases, news notes and statements
Press release 04/01/2021
Pre-pandemic data show 1 in 8 countries spends more on debt than on education, health and social protection combined – UNICEF
UNICEF is calling for the extension of debt service relief and debt restructuring so that countries – and their children – can bounce back

Press release 03/31/2021
Yemen receives 360,000 COVID-19 vaccine doses through the COVAX Facility
… The AstraZeneca vaccines licensed and manufactured by the Serum Institute of India will enable health workers and other priority populations vulnerable to COVID-19 to be protected against the virus…

Statement 03/30/2021
Statement by UNICEF Executive Director Henrietta Fore on killing of polio workers in Afghanistan
[See Polio above for detail]

Press release 03/30/2021
UNICEF fund aims to raise US$2.5 billion for COVID-19 health supplies; low- and middle-income countries set to benefit
Denmark makes first donation to support the global equitable access to COVID-19 tests, treatments and vaccines
[See COVID above for detail]

Statement 03/29/2021
UNICEF Executive Director Henrietta Fore’s remarks at the World Immunisation & Logistics Summit, hosted by the HOPE Consortium

 

Unitaid [to 3 Apr 2021]
https://unitaid.org/
Featured News
31 March 2021
Unitaid statement regarding Ivermectin as a potential COVID-19 treatment
Geneva – Ivermectin, as well as other repurposed and new products, has been under evaluation in clinical trials as a potential treatment for COVID-19.
After updating the independent living network meta-analysis, the WHO Guidelines Development Group has updated the WHO Living Guidelines: Therapeutics and COVID-19 (today March 31).  In this updated version, WHO recommends not to use ivermectin in patients with COVID-19 except in the context of clinical trials based on very low certainty of evidence.
Unitaid, in collaboration with the University of Liverpool, has tracked the evidence available for ivermectin from randomised clinical studies from around the world, with various studies still to be completed.
In addition, to support the acquisition of the necessary remaining evidence as soon as possible, the ANTICOV consortium – coordinated by DNDi and partly funded by Unitaid – is preparing to add ivermectin in a combination therapy, as a new treatment arm to the clinical trial. This large platform trial aims to identify treatments that can be used to treat mild and moderate cases of COVID-19, preventing them from progressing to severe COVID-19, and is being conducted in 13 countries in Africa, nine of which are funded by Unitaid.”

 

Vaccination Acceptance Research Network (VARN) [to 3 Apr 2021]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.

 

Vaccine Confidence Project [to 3 Apr 2021]
http://www.vaccineconfidence.org/
News, Research and Reports
Coronavirus global impact
Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 3 Apr 2021]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

 

Wellcome Trust [to 3 Apr 2021]
https://wellcome.ac.uk/news
News and reports
Explainer
Why is a global Covid-19 vaccine rollout vital?
30 March 2021

Opinion
Our new funding will support bold and creative discovery research to improve health
29 March 2021
Michael Dunn shares more information about our new discovery research funding schemes, and the role of the Discovery Research team in Wellcome’s new strategy.

 

The Wistar Institute [to 3 Apr 2021]
https://www.wistar.org/news/press-releases
Press Releases
Apr. 1, 2021
Wistar Scientists Discover New Mechanism Through Which Senescent Cells Turn On Genes That Encode for Secreted Tumor-regulating Factors
New insights into expression of the senescence-associated secretory phenotype.

 

WFPHA: World Federation of Public Health Associations [to 3 Apr 2021]
https://www.wfpha.org/
Latest News
Stop Blocking the Scale-up of Vaccines and Put Health over Profit!
Mar 31, 2021
On the occasion of World Health Day, WFPHA has joined a broad coalition of civil society organisations across Europe urgently calling on governments and EU institutions to implement a COVID-19 response based on global solidarity and to act to ensure that COVID-19 vaccines and medical products are available to everyone, everywhere in the world by waiving intellectual property rights (IPR) and sharing know-how and technology widely.

 

World Bank [to 3 Apr 2021]
http://www.worldbank.org/en/news/all
Selected News, Announcements
Event – COVID-19: Vaccines for Developing Countries
Friday, April 9th | 11:00 am ET
The rollout of COVID-19 vaccines in developing countries is critical to protecting lives, building human capital, and stimulating economic recovery. The current crisis is exacerbating inequalities throughout the world and, without access to vaccines, the gap will widen further. Ensuring developing countries can access, as well as safely distribute vaccines, calls for strong partnership and cooperation at the national, regional & global levels. This event will explore:
:: The work underway in developing countries to prepare for large scale vaccine rollouts; the strengths and gaps in country readiness; measures to ensure access and distribution; and the importance of partnerships and cooperation across all stakeholders for success.
:: The private sector’s essential role in driving innovation, production and manufacturing to meet the enormous needs for COVID-19 vaccines, tests and therapeutics.
:: Taking a broad view of COVID-19 to reflect on opportunities and challenges across research, finance and policy, as we work to build more resilient health and economic systems now –and in the future.

Government of Nepal and World Bank sign $75 million additional financing agreement for COVID-19 vaccines
KATHMANDU, April 2, 2021 – The Government of Nepal and the World Bank today signed an agreement for additional financing of $75 million to support access to safe and effective COVID-19 vaccines for…
Date: April 02, 2021 Type: Press Release

WBG Vaccine Announcement– Key Facts
COVID-19 vaccines, alongside widespread testing, improved treatment and strong health systems are critical to save lives and strengthen the global economic recovery. To provide relief for vulnerable populations…
Date: March 30, 2021 Type: Factsheet

 

World Customs Organization – WCO [to 3 Apr 2021]
http://www.wcoomd.org/
Latest News – Selected Items
30 March 2021
COVID-19 vaccine awareness: WCO completes three series of webinars involving the private sector
The World Customs Organization (WCO) successfully carried out three series of webinars between late January and late March 2021, to raise awareness about COVID-19 vaccines. The first series of webinars was held from 21 to 28 January in collaboration with Pfizer, the second from 15 to 17 March with Moderna, and the third one on 24 and 25 March with AstraZeneca.
The 11 webinars, which brought together more than 1,300 participants in total, focused on the essential specifications of COVID-19 vaccines as well as details of their distribution patterns, the aim being to make Customs better equipped to identify counterfeit or sub-standard COVID-19 vaccines at borders and curb trafficking, notably during this important period of COVID-19 vaccine delivery to governments…

 

World Organisation for Animal Health (OIE) [to 3 Apr 2021]
https://www.oie.int/en/for-the-media/press-releases/2021/
Press Releases
No new digest content identified.

 

WTO – World Trade Organisation [to 3 Apr 2021]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
World trade primed for strong but uneven recovery after COVID-19 pandemic shock
31 March 2021
Prospects for a quick recovery in world trade have improved as merchandise trade expanded more rapidly than expected in the second half of last year. According to new estimates from the WTO, the volume of world merchandise trade is expected to increase by 8.0% in 2021 after having fallen 5.3% in 2020, continuing its rebound from the pandemic-induced collapse that bottomed out in the second quarter of last year.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 3 Apr 2021]
Press Releases – Alliance for Regenerative Medicine (alliancerm.org)
Press Releases
No new digest content identified.

 

BIO [to 3 Apr 2021]
https://www.bio.org/press-releases
Press Releases
No new digest content identified.

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 3 Apr 2021]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

 

ICBA – International Council of Biotechnology Associations [to 3 Apr 2021]
https://internationalbiotech.org/news/
News
No new digest content identified.

 

IFPMA [to 3 Apr 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
COVID-19 vaccine and treatment innovators response to global leaders urgent call for international pandemic treaty
30 March 2021 –
[See Milestones above for detail]

Identification & Traceability of Medicinal Products – A tool towards strengthening health systems
30 March 2021

 

PhRMA [to 3 Apr 2021]
http://www.phrma.org/
Selected Press Releases, Statements
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
March 31, 2021
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Compassionate Force

AMA Journal of Ethics
Volume 23, Number 3 Apr 2021
https://journalofethics.ama-assn.org/issue/compassionate-force

 

Compassionate Force
Using force in caregiving is most often justified based on risk-benefit or best interest analyses. Careful, inclusive deliberation about whether force should be used in the course of a patient’s care is a rise-to-the minimum precursor of responsible force implementation, as is minimizing a patient’s risk of harm. Even when clinically indicated and ethically justifiable, force protocols drawing on physical, pharmaceutical, and legal means of restraint or seclusion can undermine therapeutic capacity in patient-clinician relationships, erode trust, and exacerbate emotional and moral distress for both patients and clinicians. These high stakes cum patients’ extreme vulnerability prompt us to consider how clinicians’ and organizations’ clinical and ethical obligations extend beyond harm minimization to compassion maximization. Although the words “compassion” and “force” rarely appear together, this issue investigates what their union could mean for and make possible in the enterprise of health care.

Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries

American Journal of Preventive Medicine
April 2021 Volume 60 Issue 4p453-594
http://www.ajpmonline.org/current

 

Research Articles
Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries
Claudia Robles, Laia Bruni, Amelia Acera,… Christine Clavel, Silvia de Sanjosé, F. Xavier Bosch
Published online: December 24, 2020
p478-487
Open Access

Preparing for SARS-CoV-2 Vaccines in US Immigrant Communities: Strategies for Allocation, Distribution, and Communication

American Journal of Public Health
April 2021 111(4)
http://ajph.aphapublications.org/toc/ajph/current

 

PERSPECTIVES
Preparing for SARS-CoV-2 Vaccines in US Immigrant Communities: Strategies for Allocation, Distribution, and Communication
Eva H. Clark, Karla Fredricks, Laila Woc-Colburn, Maria Elena Bottazzi and Jill Weatherhead
111(4), pp. 577–581

Recommendations for the Management of COVID-19 in Low- and Middle-Income Countries

American Journal of Tropical Medicine and Hygiene
Volume 104 (2021): Issue 3_Suppl (Mar 2021):
https://www.ajtmh.org/view/journals/tpmd/104/3_Suppl/tpmd.104.issue-3_Suppl.xml

 

Pragmatic Recommendations for the Management of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries
Editorial
Open access
Recommendations for the Management of COVID-19 in Low- and Middle-Income Countries
Arjen M. Dondorp, Alfred C. Papali, Marcus J. Schultz, and for the COVID-LMIC Task Force and the Mahidol-Oxford Research Unit (MORU)

Cocreated regional research agenda for evidence-informed policy and advocacy to improve adolescent sexual and reproductive health and rights in sub-Saharan Africa (

BMJ Global Health
April 2021 – Volume 6 – 4
https://gh.bmj.com/content/6/4

 

Commentary
Cocreated regional research agenda for evidence-informed policy and advocacy to improve adolescent sexual and reproductive health and rights in sub-Saharan Africa (2 April, 2021)

A scoping review of genetics and genomics research ethics policies and guidelines for Africa

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 3 Apr 2021)

 

Research article
A scoping review of genetics and genomics research ethics policies and guidelines for Africa
Authors: Joseph Ali, Betty Cohn, Erisa Mwaka, Juli M. Bollinger, Betty Kwagala, John Barugahare, Nelson K. Sewankambo and Joseph Ochieng
Citation: BMC Medical Ethics 2021 22:39
Published on: 2 April 2021
Background
Genetics and genomics research (GGR) is increasingly being conducted around the world; yet, researchers and research oversight entities in many countries have struggled with ethical challenges. A range of ethics and regulatory issues need to be addressed through comprehensive policy frameworks that integrate with local environments. While important efforts have been made to enhance understanding and awareness of ethical dimensions of GGR in Africa, including through the H3Africa initiative, there remains a need for in-depth policy review, at a country-level, to inform and stimulate local policy development and revision on the continent.
Conclusions
Enforceable policies that are indispensable to the ethical conduct and review of GGR are either deficient or missing in many African countries. Existing international, GGR-specific ethics guidelines can be used to inform GGR policy development at a country-level, in conjunction with insight from country specific ethics committees and other local stakeholders.

Research priorities for Long Covid: refined through an international multi-stakeholder forum

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 3 Apr 2021)

 

Commentary
Research priorities for Long Covid: refined through an international multi-stakeholder forum
In December 2020 ISARIC (the International Severe Acute Respiratory and emerging Infection Consortium), the research funders group GloPID-R (The Global Research Collaboration for Infectious Disease Preparedness) and global group, Long Covid Support, jointly organised a ‘Long Covid Forum’ [8]. This public forum aimed to gain a better understanding of ‘Long Covid’ and to define research priorities for funders and researchers to take forward.
Authors: Gail Carson
Citation: BMC Medicine 2021 19:84
Published on: 31 March 2021

How can community engagement in health research be strengthened for infectious disease outbreaks in Sub-Saharan Africa? A scoping review of the literature

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 3 Apr 2021)

 

How can community engagement in health research be strengthened for infectious disease outbreaks in Sub-Saharan Africa? A scoping review of the literature
Community engagement (CE) is a well-established practical and scholarly field, recognised as core to the science and ethics of health research, for which researchers and practitioners have increasingly asked q…
Authors: Samantha Vanderslott, Manya Van Ryneveld, Mark Marchant, Shelley Lees, Sylvie Kwedi Nolna and Vicki Marsh
Citation: BMC Public Health 2021 21:633
Content type: Research article
Published on: 1 April 2021

Scaling up public health interventions: case study of the polio immunization program in Indonesia

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 3 Apr 2021)

 

Scaling up public health interventions: case study of the polio immunization program in Indonesia
The scaling up of public health interventions has received greater attention in recent years; however, there remains paucity of systematic investigations of the scaling up processes. We aim to investigate the overall process, actors and contexts of polio immunization scaling up in Indonesia from 1988 until 2018.
Authors: Utsamani Cintyamena, Luthfi Azizatunnisa’, Riris Andono Ahmad and Yodi Mahendradhata
Citation: BMC Public Health 2021 21:614
Content type: Research article
Published on: 29 March 2021

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

BMJ
03 April 2021(vol 373, issue 8286)
https://www.bmj.com/content/373/8286

 

Research
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
BMJ 2021; 372 :n71 (Published 29 March 2021)
The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.

Eliminating mother-to-child transmission of human immunodeficiency virus, syphilis and hepatitis B in sub-Saharan Africa

Bulletin of the World Health Organization
Volume 99, Number 4, April 2021, 241-320
https://www.who.int/bulletin/volumes/99/4/en/

 

Eliminating mother-to-child transmission of human immunodeficiency virus, syphilis and hepatitis B in sub-Saharan Africa
— Jennifer Cohn, Morkor N Owiredu, Melanie M Taylor, Philippa Easterbrook, Olufunmilayo Lesi, Bigirimana Francoise, Laura N Broyles, Angela Mushavi, Judith Van Holten, Catherine Ngugi, Fuqiang Cui, Dalila Zachary, Sirak Hailu, Fatima Tsiouris, Monique Andersson, Dorothy Mbori-Ngacha, Wame Jallow, Shaffiq Essajee, Anna L Ross, Rebecca Bailey, Jesal Shah & Meg M Doherty
http://dx.doi.org/10.2471/BLT.20.272559

Supply chain transparency and the availability of essential medicines

Bulletin of the World Health Organization
Volume 99, Number 4, April 2021, 241-320
https://www.who.int/bulletin/volumes/99/4/en/

 

PERSPECTIVES
Supply chain transparency and the availability of essential medicines
— Christine Årdal, Enrico Baraldi, Peter Beyer, Yohann Lacotte, DG Joakim Larsson, Marie-Cécile Ploy, John-Arne Røttingen & Ingrid Smith
http://dx.doi.org/10.2471/BLT.20.267724

Artificial Intelligence in Pharmacovigilance: Scoping Points to Consider

Clinical Therapeutics
Volume 43 Issue 2 p211-430, e33-e56
http://www.clinicaltherapeutics.com/current

 

Commentary
Artificial Intelligence in Pharmacovigilance: Scoping Points to Consider
Manfred Hauben, Craig G. Hartford
Published online: January 18, 2021
Abstract
Artificial intelligence (AI), a highly interdisciplinary science, is an increasing presence in pharmacovigilance (PV). A better understanding of the scope of artificial intelligence in pharmacovigilance (AIPV) may be advantageous to more sharply defining, for example, which terms, methods, tasks, and data sets are suitably subsumed under the application of AIPV. Accordingly, this article explores relevant points to consider regarding defining the scope of AIPV and offers a potential working definition of the scope of AIPV.

An ethics framework for consolidating and prioritizing COVID-19 clinical trials

`
Clinical Trials

 

Volume 18 Issue 2, April 2021
https://journals.sagepub.com/toc/ctja/18/2
Ethics
An ethics framework for consolidating and prioritizing COVID-19 clinical trials
Michelle N Meyer, Luke Gelinas, Barbara E Bierer, Sara Chandros Hull, Steven Joffe, David Magnus, Seema Mohapatra, Richard R Sharp, Kayte Spector-Bagdady, Jeremy Sugarman, Benjamin S Wilfond, Holly Fernandez Lynch
First Published February 2, 2021; pp. 226–233
Preview
Given the dearth of established safe and effective interventions to respond to COVID-19, there is an urgent ethical imperative to conduct meaningful clinical research. The good news is that interventions to be tested are not in short supply. Unfortunately, the human and material resources needed to conduct these trials are finite. It is essential that trials be robust and meet enrollment targets and that lower-quality studies not be permitted to displace higher-quality studies, delaying answers to critical questions. Yet, with few exceptions, existing research review bodies and processes are not designed to ensure these conditions are satisfied. To meet this challenge, we offer guidance for research institutions about how to ethically consolidate and prioritize COVID-19 clinical trials, while recognizing that consolidation and prioritization should also take place upstream (among manufacturers and funders) and at a higher level (e.g. nationally). In our proposed three-stage process, trials must first meet threshold criteria. Those that do are evaluated in a second stage to determine whether the institution has sufficient capacity to support all proposed trials. If it does not, the third stage entails evaluating studies against two additional sets of comparative prioritization criteria: those specific to the study and those that aim to advance diversification of an institution’s research portfolio. To implement these criteria fairly, we propose that research institutions form COVID-19 research prioritization committees. We briefly discuss some important attributes of these committees, drawing on the authors’ experiences at our respective institutions. Although we focus on clinical trials of COVID-19 therapeutics, our guidance should prove useful for other kinds of COVID-19 research, as well as non-pandemic research, which can raise similar challenges due to the scarcity of research resources.

Blended Learning Using Peer Mentoring and WhatsApp for Building Capacity of Health Workers for Strengthening Immunization Services in Kenya

Global Health: Science and Practice (GHSP)
Vol. 9, No. 1 April 01, 2021
http://www.ghspjournal.org/content/current

 

PROGRAM CASE STUDIES
Blended Learning Using Peer Mentoring and WhatsApp for Building Capacity of Health Workers for Strengthening Immunization Services in Kenya
Iqbal Hossain, Isaac Mugoya, Lilian Muchai, Kirstin Krudwig, Nicole Davis, Lora Shimp and Vanessa Richart
Global Health: Science and Practice April 2021, 9(1):201-215; https://doi.org/10.9745/GHSP-D-20-00421
Innovative learning strategies are needed to improve frontline health workers’ skills for achieving immunization coverage goals—now even more important with COVID-19. Peer mentoring and WhatsApp networking are low-cost and useful blended learning methods for need-based and individualized capacity building of health workers for improving immunization services that don’t disrupt the health care workers’ regular work.

Lessons from the pandemic on the value of research infrastructure

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 3 Apr 2021]

 

Lessons from the pandemic on the value of research infrastructure
The COVID-19 pandemic has shed a spotlight on the resilience of healthcare systems, and their ability to cope efficiently and effectively with unexpected crises. If we are to learn one economic lesson from the…
Authors: Laurence S. J. Roope, Paolo Candio, Vasiliki Kiparoglou, Helen McShane, Raymond Duch and Philip M. Clarke
Citation: Health Research Policy and Systems 2021 19:54
Content type: Commentary
Published on: 1 April 2021

Disability inclusion in humanitarian action

Humanitarian Exchange Magazine
Number 78, October 2020
https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/

 

Disability inclusion in humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies’ lack of engagement with organisations of persons with disabilities. Simione Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a ‘participation revolution’, building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox’s Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide’s approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC’s Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD’s SADI approach.

Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses: A Systematic Review

Journal of Infectious Diseases
Volume 223, Issue 4, 15 February 2021
https://academic.oup.com/jid/issue/223/4

 

REVIEW
Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses: A Systematic Review
Tommaso Celeste Bulfone, Mohsen Malekinejad, George W Rutherford, Nooshin Razani
The Journal of Infectious Diseases, Volume 223, Issue 4, 15 February 2021, Pages 550–561, https://doi.org/10.1093/infdis/jiaa742
This systematic review found that while outdoor environments do seem at lower risk for transmission of SARS-CoV-2 and other respiratory viruses than indoor environments, there are data showing that infection transmission is possible outdoors, thus warranting further rigorous investigation.

Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults

Journal of Infectious Diseases
Volume 223, Issue 4, 15 February 2021
https://academic.oup.com/jid/issue/223/4

 

Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults
Jerald Sadoff, Els De Paepe, Wouter Haazen, Edmund Omoruyi, Arangassery R Bastian
The Journal of Infectious Diseases, Volume 223, Issue 4, 15 February 2021, Pages 699–708, https://doi.org/10.1093/infdis/jiaa409
Coadministration of Fluarix with the Ad26.RSV.preF vaccine had an acceptable safety profile and showed no evidence of interference in immune response in healthy adults aged ≥60 years.

Global Ethical Considerations Regarding Mandatory Vaccination in Children

Journal of Pediatrics
Volume 231 p1-304
http://www.jpeds.com/current

 

Reflections on Ethics and Advocacy in Child Health
Global Ethical Considerations Regarding Mandatory Vaccination in Children
Julian Savulescu, Alberto Giubilini, Margie Danchin
Published online: January 20, 2021
p10-16
Open Access
Whether children should be vaccinated against coronavirus disease-2019 (COVID-19) (or other infectious diseases such as influenza) and whether some degree of coercion should be exercised by the state to ensure high uptake depends, among other things, on the safety and efficacy of the vaccine. For COVID-19, these factors are currently unknown for children, with unanswered questions also on children’s role in the transmission of the virus, the extent to which the vaccine will decrease transmission, and the expected benefit (if any) to the child. Ultimately, deciding whether to recommend that children receive a novel vaccine for a disease that is not a major threat to them, or to mandate the vaccine, requires precise information on the risks, including disease severity and vaccine safety and effectiveness, a comparative evaluation of the alternatives, and the levels of coercion associated with each. However, the decision also requires balancing self-interest with duty to others, and liberty with usefulness. Separate to ensuring vaccine supply and access, we outline 3 requirements for mandatory vaccination from an ethical perspective: (1) whether the disease is a grave threat to the health of children and to public health, (2) positive comparative expected usefulness of mandatory vaccination, and (3) proportionate coercion. We also suggest that the case for mandatory vaccine in children may be strong in the case of influenza vaccination during the COVID-19 pandemic.

Adolescent Consent for Human Papillomavirus Vaccine: Ethical, Legal, and Practical Considerations

Journal of Pediatrics
Volume 231 p1-304
http://www.jpeds.com/current

 

Adolescent Consent for Human Papillomavirus Vaccine: Ethical, Legal, and Practical Considerations
Gregory D. Zimet, Ross D. Silverman, Robert A. Bednarczyk, Abigail English
Published online: January 20, 2021
p24-30
We address ethical, legal, and practical issues related to adolescent self-consent for human papillomavirus (HPV) vaccination. HPV vaccination coverage continues to lag well behind the national goal of 80% series completion. Structural and behavioral interventions have improved vaccination rates, but attitudinal, behavioral, and access barriers remain. A potential approach for increasing access and improving vaccination coverage would be to permit adolescents to consent to HPV vaccination for themselves. We argue that adolescent self-consent is ethical, but that there are legal hurdles to be overcome in many states. In jurisdictions where self-consent is legal, there can still be barriers due to lack of awareness of the policy among healthcare providers and adolescents. Other barriers to implementation of self-consent include resistance from antivaccine and parent rights activists, reluctance of providers to agree to vaccinate even when self-consent is legally supported, and threats to confidentiality. Confidentiality can be undermined when an adolescent’s self-consented HPV vaccination appears in an explanation of benefits communication sent to a parent or if a parent accesses an adolescent’s vaccination record via state immunization information systems. In the context of the COVID-19 pandemic, which has led to a substantial drop in HPV vaccination, there may be even more reason to consider self-consent. The atmosphere of uncertainty and distrust surrounding future COVID-19 vaccines underscores the need for any vaccine policy change to be pursued with clear communication and consistent with ethical principles.

The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study

The Lancet
Apr 03, 2021 Volume 397 Number 10281 p1237-1324, e10
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study
Stephanie J Salyer, et al
Although the first wave of the COVID-19 pandemic progressed more slowly in Africa than the rest of the world, by December, 2020, the second wave appeared to be much more aggressive with many more cases. To date, the pandemic situation in all 55 African Union (AU) Member States has not been comprehensively reviewed. We aimed to evaluate reported COVID-19 epidemiology data to better understand the pandemic’s progression in Africa.

Health data poverty: an assailable barrier to equitable digital health care

Lancet Digital Health
Apr 2021 Volume 3 Number 4 e204-e273
https://www.thelancet.com/journals/landig/issue/current

 

Viewpoint
Health data poverty: an assailable barrier to equitable digital health care
Hussein Ibrahim, Xiaoxuan Liu, Nevine Zariffa, Andrew D Morris, Alastair K Denniston
Summary
Data-driven digital health technologies have the power to transform health care. If these tools could be sustainably delivered at scale, they might have the potential to provide everyone, everywhere, with equitable access to expert-level care, narrowing the global health and wellbeing gap. Conversely, it is highly possible that these transformative technologies could exacerbate existing health-care inequalities instead. In this Viewpoint, we describe the problem of health data poverty: the inability for individuals, groups, or populations to benefit from a discovery or innovation due to a scarcity of data that are adequately representative. We assert that health data poverty is a threat to global health that could prevent the benefits of data-driven digital health technologies from being more widely realised and might even lead to them causing harm. We argue that the time to act is now to avoid creating a digital health divide that exacerbates existing health-care inequalities and to ensure that no one is left behind in the digital era.

Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study

Lancet Infectious Diseases
Apr 2021 Volume 21 Number 4 p439-578, e67-e109
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study
Diana Leticia Coronel-MartÍnez, et al.

Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials

Lancet Infectious Diseases
Apr 2021 Volume 21 Number 4 p439-578, e67-e109
https://www.thelancet.com/journals/laninf/issue/current

 

Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials
Carlos A DiazGranados, et al.

Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial

Lancet Infectious Diseases
Apr 2021 Volume 21 Number 4 p439-578, e67-e109
https://www.thelancet.com/journals/laninf/issue/current

 

Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial
Ananda S Bandyopadhyay, et al.
Open Access

The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials

Lancet Infectious Diseases
Apr 2021 Volume 21 Number 4 p439-578, e67-e109
https://www.thelancet.com/journals/laninf/issue/current

 

Personal View
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials
Jerome Amir Singh, Ross E G Upshur
Summary
An efficacious COVID-19 vaccine is currently the world’s leading research priority. Several nations have indicated that if there is a compelling case for use of a vaccine before it is licensed, they would be prepared to authorise its emergency use or conditional approval on public health grounds. As of Dec 1, 2020, several developers of leading COVID-19 candidate vaccines have indicated that they have applied, or intend to apply, for emergency authorisation for their vaccines. Should candidate vaccines attain emergency use designation and be programmatically deployed before their phase 3 trials conclude, such a strategy could have far reaching consequences for COVID-19 vaccine research and the effective control of the COVID-19 pandemic. These issues merit careful consideration.

COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics

Lancet Public Health
Apr 2021 Volume 6 Number 4 e192-e259
https://www.thelancet.com/journals/lanpub/issue/current

 

Articles
COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics
Michaël Schwarzinger, Verity Watson, Pierre Arwidson, François Alla, Stéphane Luchini

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial

Lancet Respiratory Medicine
Apr 2021 Volume 9 Number 4 p319-434, e30-e46
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial
Tracey A Day, et al for the TBVPX-203 study team

The TOPMed genomic resource for human health

Nature Reviews Genetics
Volume 22 Issue 4, April 2021
https://www.nature.com/nrg/volumes/22/issues/4

 

In Brief | 02 March 2021
The TOPMed genomic resource for human health
The TOPMed consortium report whole-genome sequencing data from 53,831 ethnically diverse participants. They describe the key features of the genetic variation and produce data resources for future medical research by the wider scientific community.
Darren J. Burgess

COVID-19 vaccines: modes of immune activation and future challenges

Nature Reviews Immunology
Volume 21 Issue 4, April 2021
https://www.nature.com/nri/volumes/21/issues/4

 

Comment | 05 March 2021
COVID-19 vaccines: modes of immune activation and future challenges
This Comment outlines how the recently licensed vaccines for COVID-19 activate innate immune mechanisms to promote immune memory to SARS-CoV-2. The authors also consider future challenges that could limit vaccine efficacy.
John R. Teijaro & Donna L. Farber

Signals of hope: gauging the impact of a rapid national vaccination campaign

Nature Reviews Immunology
Volume 21 Issue 4, April 2021
https://www.nature.com/nri/volumes/21/issues/4

 

Comment | 12 March 2021
Signals of hope: gauging the impact of a rapid national vaccination campaign
Preliminary data from Israel demonstrate real-life effectiveness of their COVID-19 vaccination campaign and provide insights that could inform rollout in other countries.
Smadar Shilo, Hagai Rossman  & Eran Segal

A Half-Century of Progress in Health: The National Academy of Medicine at 50: Emerging Infectious Diseases — Learning from the Past and Looking to the Future

New England Journal of Medicine
April 1, 2021 Vol. 384 No. 13
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
A Half-Century of Progress in Health: The National Academy of Medicine at 50: Emerging Infectious Diseases — Learning from the Past and Looking to the Future
Christopher Elias, M.D., M.P.H., John N. Nkengasong, Ph.D., and Firdausi Qadri, Ph.D.
Remarkable progress has been made in preventing deaths from infectious diseases. Now, attention could shift to focusing more resources on pandemic preparedness, including detecting and containing emerging zoonotic threats while they are localized and manageable.

Brief Report: Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease

New England Journal of Medicine
April 1, 2021 Vol. 384 No. 13
http://www.nejm.org/toc/nejm/medical-journal

 

Original Articles
Brief Report: Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease
Placide Mbala-Kingebeni, M.D., Ph.D. et al
Summary
During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)